Cholesterol synthesis and regulation

Cholesterol Overview - Friend & Foe

• Physiologic Roles (Friend):
  • Maintains cell membrane fluidity.
  • Precursor for: steroid hormones (e.g., cortisol), bile acids, and Vitamin D.
• Pathologic Role (Foe):
  • Excess deposition in vessel walls leads to atherosclerosis, the basis of coronary artery disease.

⭐ The majority of the body's cholesterol is synthesized de novo, primarily by the liver, rather than from dietary sources.

Synthesis Pathway - The Mevalonate Route

• Location: Primarily occurs in the cytosol of liver cells (hepatocytes).

• Substrate: Starts with Acetyl-CoA, derived from mitochondrial citrate.

• Key Intermediates:

  • Two Acetyl-CoA molecules combine to form acetoacetyl-CoA.
  • This reacts with another Acetyl-CoA to form HMG-CoA (3-hydroxy-3-methylglutaryl-CoA).

• Rate-Limiting Step: The irreversible conversion of HMG-CoA to Mevalonate.

  • Enzyme: HMG-CoA reductase. This is the principal site of regulation.
  • Cofactor: Requires 2 NADPH for the reduction reaction.

• Final Stages: Mevalonate is converted to activated isoprenes, which polymerize to form squalene. Squalene then cyclizes and is modified to form the final cholesterol molecule.

⭐ HMG-CoA reductase is the key rate-limiting enzyme in cholesterol synthesis. Its activity is tightly regulated and it serves as the pharmacological target for statin medications.

Regulation Station - Controlling Cholesterol

• Rate-Limiting Enzyme: HMG-CoA Reductase, which converts HMG-CoA to mevalonate.

  • Primary Site: Cytosol of hepatocytes.
  • Therapeutic Target: Statins act as competitive inhibitors.

• Core Regulatory Pathways:

  • Transcriptional Control (SREBP-2):
    • Low Sterol Levels: SREBP-2 (Sterol Regulatory Element-Binding Protein-2) translocates to the nucleus, binding to the SRE (Sterol Response Element) on DNA → ↑ transcription of HMG-CoA reductase.
    • High Sterol Levels: SREBP-2 is retained in the ER → ↓ transcription.
  • Hormonal Regulation:
    • Insulin & Thyroxine: Upregulate (activate phosphatase → dephosphorylate enzyme).
    • Glucagon & Epinephrine: Downregulate (activate AMP-activated protein kinase → phosphorylate enzyme).
  • Feedback Inhibition: Allosterically inhibited by high levels of cholesterol and mevalonate.

⭐ Statins' Dual Benefit: Beyond inhibiting cholesterol synthesis, statins cause a compensatory upregulation of LDL receptors on hepatocytes, which enhances the clearance of LDL cholesterol from the circulation.

High‑Yield Points - ⚡ Biggest Takeaways

• HMG-CoA reductase is the rate-limiting enzyme, converting HMG-CoA to mevalonate.
• Statins are competitive inhibitors of this key enzyme, effectively lowering cholesterol.
• Synthesis is upregulated by insulin and thyroxine; downregulated by glucagon and cholesterol.
• The entire process occurs in the cytosol, starting from Acetyl-CoA.
• Cholesterol is the precursor to steroid hormones, bile acids, and vitamin D.
• SREBP-2 is the major transcription factor activating synthesis when cholesterol is low.